Sodium glucose transporter 2 (SGLT2) inhibitors, originally approved solely as antihyperglycemic agents for the treatment of type 2 diabetes mellitus (T2DM), are increasingly recognized for their distinctive kidney and cardiovascular protective properties.1 From a kidney perspective, in people with T2DM in the CREDENCE trial with estimated glomerular filtration rate (eGFR) of 30 to